Explore the Latest Tocilizumab Tenders on Tender Impulse - Your Trusted Global Tender Website
Are you searching for the latest Tocilizumab Tenders from trusted sources across the globe? Tender Impulse is the go-to tender website for businesses seeking verified, timely updates on public tenders, government tenders and business tenders.
With real-time data and smart filters, you can find the most relevant Tocilizumab Tenders issued by ministries, public sector organisations and international procurement agencies - whether you're an SME or a multinational.
All-in-One Platform for Tocilizumab Tenders
- Requests for Proposals (RFPs) & Quotations (RFQs)
- General Procurement Notices (GPNs) & Expressions of Interest (EOIs)
- Prequalification documents, contract awards and amendments
Why Choose Tender Impulse?
- Custom email alerts tailored to your industry.
- Global coverage across 190+ countries and every major sector.
- Instant document access - specifications, BOQs and tender forms.
- Advanced filters by country, industry, deadline, value and procurement type.
Request a free live demo today and explore thousands of Tocilizumab Tenders and beyond.
6408961Germany Pharmaceutical products Open house Arzneimittelrabattvertrge Tocilizumab ATC L04AC07Country: GermanyDeadline05 Nov 20269321731Germany Pharmaceutical products Abschluss eines nicht exklusiven Rabattvertrages nach 130a Abs 8 SGB V zu Arzneimitteln mit dem Wirkstoff Tocilizumab ATC-Code L04AC07Country: GermanyDeadline27 Aug 20279382212Germany Pharmaceutical products Open-House-Biologika-Rabattvertrge 2025-27 - TocilizumabCountry: GermanyDeadline31 Oct 20269679106Germany Pharmaceutical products Abschluss nicht exkl Arzneimittel-Rabattvereinb nach 130a Abs 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Tocilizumab ATC-Code nach WHCountry: GermanyDeadline31 Dec 20269695674Conclusion not excluding drug discount agreement according to section 130a paragraph 8 sgb v through an open house model for the active ingredient tocilizumab atc code accordingCountry: GermanyDeadline01 Jan 20279807932Germany Pharmaceutical products Open house Arzneimittelrabattvertrge zum Wirkstoff Tocilizumab ATC L04AC07Country: GermanyDeadline30 Sep 20279814376Germany Pharmaceutical products Abschluss einer nicht-exklusiven Rabattvereinbarung nach 130a Abs 8 SGB V zum Wirkstoff Tocilizumab ausschlielich Fertigspritze und Fertigpen ATCCountry: GermanyDeadline05 Oct 20279814594Germany Pharmaceutical products Abschluss einer nicht-exklusiven Rabattvereinbarung nach 130a Abs 8 SGB V zum Wirkstoff Tocilizumab ausschlielich Infusionslsungskonzentrat ATC LCountry: GermanyDeadline05 Oct 20279853523Germany Pharmaceutical products Abschluss nicht exkl Arzneimittel-Rabattvereinb nach 130a Abs 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Tocilizumab ATC-Code nach WHCountry: GermanyDeadline31 Dec 202610232453Germany Pharmaceutical products Arzneimittel mit dem Wirkstoff Tocilizumab ATC L04AC07 - zur subkutanen AnwendungCountry: GermanyDeadline31 Oct 202710244192Medicines with the active ingredient tocilizumab atc l04ac07 - for subcutaneous useCountry: GermanyDeadline31 Oct 202711970271Germany Pharmaceutical products Open-House-Biologika-Rabattvertrge 2026-07 - TocilizumabCountry: GermanyDeadline30 Apr 202812003788Open house biologics discount agreements 2026-07 - tocilizumabCountry: GermanyDeadline01 May 202813095339Open House Biologics Discount Agreements 2025-27 - TocilizumabCountry: GermanyDeadline31 Oct 202613185737Open House Biologics Discount Agreements 2025-27 - TocilizumabCountry: GermanyDeadline31 Oct 202613315753Open House Biologics Discount Agreements 2025-27 - TocilizumabCountry: GermanyDeadline31 Oct 202613363958Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Tocilizumab (ausschließlich Darreichungsform PEN und FER), ATC L04AC07 für die Zeit 01Country: GermanyDeadline04 Jun 202813439180Open House Biologics Discount Agreements 2025-27 - TocilizumabCountry: GermanyDeadline31 Oct 202613536131Open House Biologics Discount Agreements 2025-27 - TocilizumabCountry: GermanyDeadline31 Oct 202613602179Framework agreement for the supply of TocilizumabCountry: BelgiumDeadline10 Aug 202613679352Open House Biologics Discount Agreements 2025-27 - TocilizumabCountry: GermanyDeadline31 Oct 202613952187Request for Proposals - Supply of rituximab, infliximab and tocilizumabCountry: New ZealandDeadline02 Sep 202614190165Arzneimittel mit dem Wirkstoff Tocilizumab (ATC: L04AC07)Country: GermanyDeadline31 Jul 202814248072SUPPLY OF TOCILIZUMAB 80MG 4ML 200MG 10ML AND 400MG 20ML FOR INTRAVENOUS USE AND 162MG 0 9ML FOR SUBCUTANEOUS USE FOR THE HOSPITAL PHARMACYCountry: BelgiumDeadline07 Sep 202614257919LEVEREN VAN TOCILIZUMAB 80MG/4ML, 200MG/10ML EN 400MG/20ML VOOR INTRAVENEUS GEBRUIK EN 162MG/0.9ML VOOR SUBCUTAAN GEBRUIK VOOR DE ZIEKENHUISAPOTHEEKCountry: BelgiumDeadline07 Sep 2026
